Goodwin Procter advised Acadia Pharmaceutical on the deal while Wilson Sonsini represented Stoke Therapeutics.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced its collaboration agreement with Stoke Therapeutics, Inc. (Nasdaq: STOK) to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system (CNS). The collaboration includes SYNGAP1 syndrome, Rett syndrome (MECP2), and an undisclosed neurodevelopmental target of mutual interest.
Acadia developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Acadia’s late-stage development efforts are focused on treating psychosis in patients with dementia, the negative symptoms of schizophrenia and Rett syndrome.
Stoke is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines.
Under the terms of the agreement, Stoke will receive an upfront payment of $60 million from Acadia and is eligible to receive up to $907 million in milestones as well as royalties on future sales.
The Goodwin team was led by Chris Denn (Picture), Daniel Karelitz, and Paresh Kumar, with invaluable input from Theresa Kavanaugh and Paul Jin, and support from Rebecca Garverman.
The Wilson Sonsini team included Vern Norviel, Lou Lieto, Chris McAndrew, Wei Huang, and Swati Sharma.
Involved fees earner: Christopher Denn – Goodwin Procter; Rebecca Garverman – Goodwin Procter; Paul Jin – Goodwin Procter; Daniel Karelitz – Goodwin Procter; Theresa Kavanaugh – Goodwin Procter; Paresh Kumar – Goodwin Procter; Wei Huang – Wilson Sonsini Goodrich & Rosati; Louis Lieto – Wilson Sonsini Goodrich & Rosati; Vern Norviel – Wilson Sonsini Goodrich & Rosati;